Member Info for Taff8

OK glencore under control of eleven group, will they buy stonepark from group eleven?? Their mine down the road is one of the biggest underground zinc mine in the world, stonepark higher grades, gotta be worth few $billion of zinc & lead there, the mine as it is must be worth £50m(£12.5m/6p ark)???

Think about it 25% for what £6m/3p share t/o??

Wouldn't be surprised to see glencore t/o ARk

Here we go mkt cap sub £2m

Higher grades than Glencore's mine next door, can't believe this isn't already 3p/6m mkt cap

Zinc price $2000 per tonne

This joint venture with Group Eleven in County Limerick, contains a maiden
Inferred Mineral Resource totalling 5.1 million tonnes at 11.3% zinc and lead
combined (8.7% Zn and 2.6% Pb), occurring at depths from 190m to 395m below
surface. The Project lies adjacent to Glencore's Pallas Green deposit which
contains 45.4 million tonnes at 8% zinc and lead combined (Glencore; Resources
and Reserves as at December 31, 2019).

25% free ride, this mine is huge just look at the zinc grades

Just can't believe how cheap these are, won't post again then.

N4 Pharma, the specialist pharmaceutical company developing Nuvec, a novel delivery system for cancer treatments and vaccines, announces that it will be undertaking a proof of concept research project using a Covid-19 DNA plasmid for the purpose of demonstrating the ability of Nuvec to be used as a delivery system by potential collaboration partners developing Covid-19 DNA or RNA vaccines.

The net proceeds of the Placing will be applied to:

o expand the proof of concept research on the Covid-19 DNA plasmid project, as announced on 25 March 2020;

o increased manufacture of the Nuvec® nanoparticle for further collaboration with partners;

o further studies on the use of Nuvec® to support the recently filed patent on use of Nuvec® for viral vector manufacture; and

o fund the continued growth of the Company, including for working capital purposes.

· Mixture of new and existing institutional and other investors took part in the Placing.

further ten weeks, commencing in mid-July.

Once the stage 3 results have been reviewed, the Company will then determine whether to do a further in vivo study to demonstrate the capability of Nuvec® to generate Covid-19 specific antibodies. In light of the current global urgency around treatments for Covid-19, the Company would also seek to collaborate, where it can, with appropriate partners to accelerate further studies at this juncture.

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, announces
that it has filed a new UK patent application around both Nuvec®'s ability to
be used to manufacture viral vectors and to make viral vectors more efficient
in applications such as ex-vivo gene therapy treatments.

Cancer immunotherapies and viral vaccines that are nucleic acid-based can be challenging to formulate and require highly specific delivery systems. Commonly adopted delivery systems, such as lipid nanoparticles and viral vectors, can have limited efficacy, associated risks, or in some cases, may have unknown long-term safety profiles.

N4 Pharma have been developing an alternative approach: Nuvec® – silica nanoparticles, a unique and non-viral adjuvant delivery system.

Technology Networks recently spoke with Nigel Theobald, CEO and Founder of N4 Pharma, to learn more about nanoparticle drug delivery, the Nuvec® platform and its progress towards clinical trials.

We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.

#N4P
Last week CEO would have been focusing on getting #Nuvec noticed at the partnering event.

High loading capabilities.
Low toxicity issues, well tolerated.
NO systemic cytokines noticed.
Local degradation only, no leakage.
Easily mass scalable

Look at the names they are had virtual meetings
??Roche
??Merck
??Astra Zeneca
??Gilead
??Fuson pharma
??Sanofi
??Pfizer

Agree 10bagger all over this, how the hell it still only £5m mkt cap?

They always wait until the traders are out first, always happens, watch this move over the next few weeks.

* U.K.-based Tiziana says its TZLS-501 could be a potential treatment for patients infected with coronavirus (COVID-19) who are at a risk of respiratory failure...
* Tests have already shown that treatment rapidly depletes circulating levels of IL-6 in the blood, co says in a statement
* An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness
* Co is expediting development of TZLS-501 with Swiss biotechnology firm Novimmune SA